• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of clinical pharmacology =: Journal canadien de pharmacologie clinique >Pharmacokinetic comparison of a delayed- release combination of doxylamine succinate and pyridoxine hydrochloride (diclectin?) and oral solutions of these drugs in healthy women of childbearing age
【24h】

Pharmacokinetic comparison of a delayed- release combination of doxylamine succinate and pyridoxine hydrochloride (diclectin?) and oral solutions of these drugs in healthy women of childbearing age

机译：琥珀酸多西拉敏胺盐酸盐和吡ine醇盐酸盐（diclectin？）的延迟释放组合与这些药物在育龄妇女中的口服溶液的药代动力学比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The delayed-release combination of doxylamine succinate and pyridoxine hydrochloride was the most commonly used antiemetic (Bendectin) approved by FDA for nausea and vomiting of pregnancy (NVP) until its removal of the market in 1983. The drug is widely used today in Canada (Diclectin?). The pharmacokinetics of Diclectin? has never been described in humans. Objectives: To compare the pharmacokinetics of Diclectin? to oral solutions of its two components. Subjects and Methods: A randomized, cross over, open label design, comparing the pharmacokinetics of Diclectin? to those of the oral solutions of the two components in 18 healthy adult, non pregnant women of childbearing age. Results: Diclectin? exhibited similar oral bioavailability to those of the oral solutions. In contrast, the time-topeak, (Tmax), reflecting the rate of absorption, was 3-6 times longer for the two components of the delayed-release drug confirming its delayed-release characteristics. Conclusion: The pharmacokinetic profile of Diclectin? well explains its documented delayed efficacy.
机译：背景：琥珀酸多西拉敏胺和盐酸吡ido醇的延迟释放组合是FDA批准的最常用的止吐药（Bendectin），直到1983年投放市场后才用于恶心和妊娠呕吐（NVP）。该药物在今天已广泛用于加拿大（Diclectin？）。 Diclectin的药代动力学？从未在人类中描述过。目的：比较Diclectin的药代动力学？口服液的两个组成部分。受试者和方法：随机，交叉，开放标签设计，比较Diclectin？的药代动力学。与18个健康成年，未生育年龄的健康孕妇的两种成分的口服溶液相比。结果：Diclectin？具有与口服溶液相似的口服生物利用度。相反，对于缓释药物的两种成分而言，反映吸收速率的时间（Tmax）则要长3-6倍，从而证实了其缓释特性。结论：Diclectin的药代动力学特征？很好地解释了其记录的延迟疗效。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号